---
markmap:
  colorFreezeLevel: 6
---

# Anti-HIV Drugs (ART)

## Classifications & Mechanisms

- ### Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs)
  - Mechanism: Analogs incorporated into viral DNA chain -> chain termination
  - Key Drugs:
    - Zidovudine (AZT): 1st drug, Myelosuppression, Pigmentation
    - Stavudine (d4T) & Didanosine (ddI): Peripheral Neuropathy, Pancreatitis, Lactic Acidosis (less used now)
    - Lamivudine (3TC) & Emtricitabine (FTC): Well tolerated, cross-resistance
    - Abacavir (ABC): Hypersensitivity reaction (HLA-B*5701 testing)
    - Tenofovir Disoproxil Fumarate (TDF): Nephrotoxicity (Fanconi), Bone demineralization
    - Tenofovir Alafenamide (TAF): Prodrug, less renal/bone toxicity
- ### Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  - Mechanism: Bind non-competitively to RT -> conformational change -> inhibition
  - Key Drugs:
    - Nevirapine (NVP): Rash (SJS/TEN), Hepatotoxicity
    - Efavirenz (EFV): CNS effects (dizziness, dreams), Teratogenic (neural tube defects - avoid 1st trimester)
    - Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR): Newer, better tolerated, interactions
  - Note: Do NOT require intracellular phosphorylation
- ### Protease Inhibitors (PIs)
  - Mechanism: Inhibit viral protease -> prevents cleavage of polyproteins -> immature non-infectious virions
  - Key Drugs:
    - Ritonavir (RTV) & Cobicistat (COBI): PK Boosters (inhibit CYP3A4)
    - Lopinavir/Ritonavir (LPV/RTV): Standard combo
    - Atazanavir (ATV): Unconjugated Hyperbilirubinemia ("bananavir"), PR interval prolongation
    - Darunavir (DRV): Requires boosting, Sulfa moiety (caution in sulfa allergy)
  - Class Effects: Metabolic (Lipodystrophy, Hyperglycemia, Dyslipidemia), GI upset, Drug interactions (CYP3A4 inhibition)
- ### Integrase Strand Transfer Inhibitors (INSTIs)
  - Mechanism: Inhibit viral integrase -> prevents integration of viral DNA into host genome
  - Key Drugs:
    - Raltegravir (RAL): Fewest drug interactions (metabolized via UGT1A1)
    - Elvitegravir (EVG): Requires boosting (COBI), combined with TDF/TAF+FTC (STRIBILD, Genvoya)
    - Dolutegravir (DTG): High barrier to resistance, few interactions (chelated by polyvalent cations), potential link to neural tube defects (updated guidance), weight gain
    - Bictegravir (BIC): Combined with TAF+FTC (BIC/TAF/FTC - Biktarvy), chelated by polyvalent cations
- ### Entry/Fusion Inhibitors
  - Mechanism: Prevent virus from entering host cell
  - Key Drugs:
    - Enfuvirtide (T-20): Fusion Inhibitor, SC injection, injection site reactions
    - Maraviroc (MVC): CCR5 Antagonist, requires Tropism Test (only works for CCR5 tropic virus), Hepatotoxicity

## Key Side Effects & Considerations

- Lactic Acidosis & Hepatic Steatosis: NRTIs (especially Stavudine, Didanosine, Zidovudine)
- Peripheral Neuropathy: Stavudine, Didanosine (NRTIs)
- Pancreatitis: Didanosine, Stavudine (NRTIs)
- Myelosuppression: Zidovudine (NRTI)
- Nephrotoxicity & Bone Toxicity: Tenofovir TDF > TAF (NRTI)
- Hypersensitivity Reaction: Abacavir (NRTI - HLA-B*5701)
- Rash (SJS/TEN): Nevirapine (NNRTI), potentially others
- Hepatotoxicity: Nevirapine (NNRTI), Maraviroc (Entry Inhibitor)
- CNS Effects: Efavirenz (NNRTI - dreams, dizziness, depression)
- Teratogenicity: Efavirenz (NNRTI - avoid 1st trimester), Dolutegravir (INSTI - potential risk)
- Metabolic Syndrome (Lipodystrophy, Dyslipidemia, Hyperglycemia): PIs
- Drug Interactions: PIs (CYP3A4 inhibition), NNRTIs (CYP induction/inhibition), INSTIs (chelation by polyvalent cations)
- Immune Reconstitution Inflammatory Syndrome (IRIS): With ART initiation

## INICET Buzzwords / Concepts

- ART Regimens
- HAART (Highly Active Antiretroviral Therapy)
- Viral Load, CD4 count
- Resistance testing
- Tropism test (Maraviroc)
- HLA-B*5701 (Abacavir)
- PEP (Post-Exposure Prophylaxis)
- PrEP (Pre-Exposure Prophylaxis)
- Pregnancy (preferred regimens)
- Lactic Acidosis
- Lipodystrophy
- IRIS
- SJS/TEN
- Boosters (Ritonavir, Cobicistat)
